Research
Hormonal
Tirzepatide (10-15 mg weekly) is more effective than placebo in resolving MASH without worsening fibrosis, showing substantial weight loss and metabolic improvements.
Tirzepatide (10-15mg weekly) is more effective than placebo for resolving MASH without worsening fibrosis. It causes significant weight loss and has an acceptable safety profile.
GoodSupportsHIGH confidence
New clinical research about tirzepatide for MASH with liver fibrosis published in 2024 showed that treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis... once-weekly tirzepatide (10 mg or 15 mg) in Chinese adults with obesity or overweight resulted in significant and clinically meaningful weight reduction with an acceptable safety profile, and weight loss is beneficial for attenuation of MASLD.
Why this rating
Based on 2024 clinical trial data.
Source
Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Da Zhou et al. · Chinese Medical Journal · 2024
DOI 10.1097/cm9.0000000000003355
narrative_reviewCited 16×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Resmetirom (80-100 mg daily) is the first FDA-approved pharmacotherapy for MASH with fibrosis, demonstrating significant improvement in liver fibrosis and MASH resolution compared to placebo.Good
- GLP-1 receptor agonists (e.g., semaglutide, liraglutide) improve MASH resolution but do not significantly improve liver fibrosis in patients with compensated cirrhosis.Good
- Pioglitazone (30-45 mg) improves hepatic steatosis and inflammation in MASH patients, particularly those with type 2 diabetes, but carries risks of weight gain and bone fractures.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →